Compare GLDG & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLDG | INBX |
|---|---|---|
| Founded | 2009 | 2010 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 317.0M | 430.2M |
| IPO Year | N/A | 2020 |
| Metric | GLDG | INBX |
|---|---|---|
| Price | $1.33 | $76.74 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | ★ $3.50 | N/A |
| AVG Volume (30 Days) | ★ 2.5M | 236.0K |
| Earning Date | 10-10-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,400,000.00 |
| Revenue This Year | N/A | $563.00 |
| Revenue Next Year | N/A | $230.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.71 | $10.81 |
| 52 Week High | $1.80 | $94.47 |
| Indicator | GLDG | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 45.38 | 46.07 |
| Support Level | $1.31 | $79.00 |
| Resistance Level | $1.48 | $94.47 |
| Average True Range (ATR) | 0.07 | 5.90 |
| MACD | -0.01 | -2.08 |
| Stochastic Oscillator | 7.55 | 5.29 |
GoldMining Inc is a mineral exploration company with a focus on the acquisition, exploration, and development of projects in Colombia, Brazil, the United States, Canada, and Peru. The principal projects are its La Mina Gold project and its Titiribi Gold-Copper project, located in Colombia; Crucero project, located in Peru; Sao Jorge, Batistao, located in Brazil; Yellowknife Gold Project, located in the Northwest Territories, Canada; and various other projects such as Cachoeira, Yarumalito, Whistler, Surubim, Montes Aureos and Trinta, Rea across different locations. The company has two operating segments, with U.S. GoldMining being one distinct operating segment and all other subsidiaries, or Others, being the second operating segment.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.